Quarterly Activity Report – Quarter Ending 30 September 2022

 Highlights: Imagion presented prostate cancer research data at World Molecular Imaging Conference (WMIC)  Receipt of $2.5 million R&D tax incentive…


Imagion Biosystems receives AU$2.5 million in R&D tax incentives

ASX Announcement: MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is…


The Market Herald Interview Discussing First-of-its-Kind Magnetic Imaging Technology

We recently announced that our MagSense® diagnostic technology has the potential to target prostate cancer tumors, making this the second cancer type the…


2022 Switzer Small & Micro Cap Conference Presentation

Imagion Bio CEO, Robert Proulx, presents company information to investors at the 2022 Switzer Small & Micro Cap Conference in September. Video Transcript:…


Half-Year Results for the First Half of 2022 and Appendix 4D

Today, we released our Appendix 4D and Half-Year Financial Report for the half-year ending 30 June 2022 to the ASX. 1H2022 Highlights: MagSense® HER2 breast…


Q&A Session at 2022 Annual General Meeting

Imagion Biosystems recording of the Q&A session at the 2022 Annual General Meeting. Imagion Biosystems' board of directors answer questions from…


Results of 2022 Annual General Meeting

In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, Imagion Biosystems Limited advises the results of its Annual…


Presentation Visuals from 25th May 2022 Annual General Meeting

The presentation visuals from the 25th May 2022 Annual General Meeting are now available. You can find the 2022 AGM Investor Presentation here.    …


Chairman’s Address to Shareholders at 2022 Annual General Meeting

Imagion Biosystems recording and transcript of the Chairman’s address to shareholders at the 2022 Annual General Meeting. Dear Shareholders, It is my…


Ticker News Interview - Breast Cancer Clinical Trial Update

Bob Proulx discusses updates on the first-in-human MagSense® HER2 breast cancer clinical trial with TickerTV - trial is progressing positively.  …